Clinical Trials Logo

COPD Exacerbation clinical trials

View clinical trials related to COPD Exacerbation.

Filter by:

NCT ID: NCT05721833 Not yet recruiting - COPD Exacerbation Clinical Trials

Effect of Noninvasive High Frequency Oscillatory Ventilation on Improving CO2 Clearance in COPD Patients

Start date: February 10, 2023
Phase: N/A
Study type: Interventional

High-frequency oscillatory ventilation (HFOV), as an ideal lung-protecting ventilation method, has been gradually used in neonatal critical care treatment, and is currently recommended as a rescue method for neonatal acute respiratory distress syndrome (ARDS) after failure of conventional mechanical ventilation. . Although its ability to improve oxygenation and enhance carbon dioxide (CO2) scavenging has been repeatedly demonstrated in laboratory studies, its impact on clinical outcomes in these patients remains uncertain. Non-invasive high-frequency oscillatory ventilation (nHFOV) combines the advantages of HFOV and non-invasive ventilation methods, and has become a current research hotspot in this field. It is recommended to be used to avoid intubation after conventional non-invasive ventilation therapy fails. For the treatment of intubation, there is still a lack of large-scale clinical trials to systematically explore its efficacy. The gradual increase in the clinical application of nHFOV has also enriched its use in the treatment of other diseases

NCT ID: NCT05703919 Not yet recruiting - COPD Exacerbation Clinical Trials

Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease

STOP-COPD
Start date: March 1, 2025
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to test titrated oxygen in prehospital patients with suspected acute exacerbation of chronic obstructive pulmonary disease (AECOPD) treated with inhaled bronchodilators. The main question it aims to answer is: - To determine whether prehospital titrated oxygen strategy in patients with suspected AECOPD will decrease 30-day mortality compared to patients receiving standard care. Participants in the intervention will receive titrated oxygen - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 (oxygen saturation) 88-92%. The intervention will be compared to standard treatment, using compressed oxygen (100%) as driver for inhaled bronchodilators.

NCT ID: NCT05598983 Not yet recruiting - COPD Exacerbation Clinical Trials

Non-contact Proactive Remote Monitoring of COPD Exacerbations

DetectEx
Start date: May 15, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to determine if a COPD exacerbation can be detected early in its onset. The main questions it aims to answer are: - Can an exacerbation be detected before the person recognizes they are unwell? - What are the biological signals which provide the best indication of decompensation? - How does this indication of decompensation compare to a daily CAT? Participants will be asked to place a device, DistaSense, on top of their mattress and then sleep as normal. In addition, they will be asked to complete a daily CAT.

NCT ID: NCT05491408 Not yet recruiting - COPD Exacerbation Clinical Trials

Effect of Cough Assist Device in COPD Patients Admitted to Respiratory Intensive Care Unit at Assiut University Hospital

Start date: August 1, 2022
Phase:
Study type: Observational

1. To evaluate the effecacy of cough assist device (CAD) in COPD patients admitted in RICU either on invasive or Non-invasive ventilation. 2. To detect any possible complications associated with the use of cough assist device.

NCT ID: NCT05370664 Not yet recruiting - COPD Exacerbation Clinical Trials

Performance of Novel Bed Side Scores as Predictors of Hospital Outcome in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Among Women; Cohort Study

Start date: July 2022
Phase:
Study type: Observational

- Assess predictors of mortality in COPD exacerbation between men and women. - Evaluate the clinical outcomes in acute exacerbation of COPD in women. - Evaluate the validity of new scoring systems ( NIVO, DECAF, HACOR ) as a predictor for hospital outcome in acute exacerbation of COPD. - Compare these new scoring system with the most widely used APACHE IV. - Assessment of serum level of granulocyte colony stimulating factor ( GM-CSF) in detecting the severity of COPD exacerbation.

NCT ID: NCT05213507 Not yet recruiting - COPD Clinical Trials

Inhaled Amikacin in Preventing AECOPD

Start date: March 2022
Phase: Phase 3
Study type: Interventional

The underlying bacterial colonization in lower respiratory tract (LRT) of COPD patients may be related to acute exacerbation of COPD (AECOPD) and disease progression. However, there is a lack of strong evidence on the effect of LRT bacterial decolonization on COPD. This study was designed to confirm the prophylactic effect of decolonization of LRT bacteria on AECOPD and establish a novel prophylactic therapy for sable COPD.

NCT ID: NCT04737655 Not yet recruiting - COPD Exacerbation Clinical Trials

Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care

TRIMICU
Start date: February 15, 2021
Phase: Phase 4
Study type: Interventional

Objective: To evaluate non-inferiority of Trimbow, an approved therapy for treatment of severe COPD, in ICU compared to the standard of care which is based on the same therapeutic approach. Study location: CHU Sart-Tilman, 4000 Liège, Belgium Study duration: 2 years Type : Interventional Methodology: Prospective clinical trial Number of patients: 200 (randomized 1:1) Main Inclusion criteria : - Maintenance therapy (LAMA or LABA) for COPD - Age >18 - Admission for AE of COPD - Signed Inform consent - Admitted in ICU >24h

NCT ID: NCT04694430 Not yet recruiting - COPD Exacerbation Clinical Trials

A Multi-center Study to Determine the Prevalence and Influence of Pertussis on COPD Exacerbation in Shenzhen

Start date: January 1, 2021
Phase:
Study type: Observational

A prospective, multi-center, observational clinical trail. Aim to evaluate the real incidence of chronic obstructive pulmonary disease (COPD) pertussis and the impact of pertussis on COPD exacerbation.

NCT ID: NCT04671888 Not yet recruiting - COPD Clinical Trials

Chronic Obstructive Pulmonary Disease (COPD) Monitoring

COPD
Start date: February 2021
Phase: N/A
Study type: Interventional

The present feasibility study aims at assessing whether the EMG of respiratory muscles can serve as an objective marker of dyspnea in COPD patients. The study aims also at evaluating the changes in physiological parameters (i.e., EMG, respiration rate, heart rate, temperature, and SpO2) occurring when simulating daily activities before, during and after acute exacerbations. All this information can be useful to detect the exacerbations earlier or to provide better treatment during the exacerbations.

NCT ID: NCT04509128 Not yet recruiting - COPD Clinical Trials

Ultrasonographic Evaluation of Diaphragm and Quadriceps in Chronic Obstructive Pulmonary Disease (COPD) Patients

EDIFEB
Start date: December 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the prognostic role of echographic diaphragmatic assessment and vastus lateralis muscle ultrasound (US) in two independent populations of patients hospitalized for exacerbated Chronic Obstructive Pulmonary Disease (COPD) or undergoing pulmonary rehabilitation. Specific aims of this protocol are: 1) to analyze the correlation between qualitative and quantitative US parameters and severity of illness indicators and respiratory function data; 2) to detect the postrehabilitation outcomes in terms of diaphragmatic and vastus lateralis muscle function, assessed by US, and the correlation between these outcomes and indicators of pulmonary rehabilitation treatment effectiveness; 3) to evaluate the ability of qualitative and quantitative US parameters to predict in-hospital mortality and length of stay; 4) to evaluate the ability of qualitative and quantitative US parameters to predict exacerbation rate, hospitalization rate and mortality rate six months after the discharge.